OraSure Technologies (OSUR) Stock Overview
Develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Risk Analysis
No risks detected for OSUR from our risk checks.
OSUR Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
OraSure Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.14 |
| 52 Week High | US$4.61 |
| 52 Week Low | US$2.36 |
| Beta | 0.27 |
| 1 Month Change | -6.55% |
| 3 Month Change | 13.36% |
| 1 Year Change | -28.31% |
| 3 Year Change | -21.11% |
| 5 Year Change | -73.21% |
| Change since IPO | -42.91% |
Recent News & Updates
OraSure Technologies, Inc. (NASDAQ:OSUR) Analysts Are Pretty Bullish On The Stock After Recent Results
Aug 08
OraSure Technologies: An Asymmetric Bet
Jul 28Recent updates
OraSure Technologies, Inc. (NASDAQ:OSUR) Analysts Are Pretty Bullish On The Stock After Recent Results
Aug 08OraSure Technologies: An Asymmetric Bet
Jul 28Shareholders Will Probably Hold Off On Increasing OraSure Technologies, Inc.'s (NASDAQ:OSUR) CEO Compensation For The Time Being
May 08Investors Don't See Light At End Of OraSure Technologies, Inc.'s (NASDAQ:OSUR) Tunnel And Push Stock Down 26%
Feb 27
Launch Of OraQuick HCV Self-Test And Genomics Ventures Will Open Markets Amid Profitability Pressures
The international launch of the OraQuick HCV Self-test and upcoming blood proteomics launch offer significant revenue and growth opportunities.OraSure Technologies: Discounted Assets With An Attractive Free Call Option
Dec 11Some May Be Optimistic About OraSure Technologies' (NASDAQ:OSUR) Earnings
Nov 14Here's What Analysts Are Forecasting For OraSure Technologies, Inc. (NASDAQ:OSUR) After Its Third-Quarter Results
Nov 08OraSure: An NCAV Diamond In The COVID Rough
Nov 04OraSure Technologies: Nursing A COVID-19 Hangover
Sep 10OraSure Technologies, Inc. (NASDAQ:OSUR) Just Reported Earnings, And Analysts Cut Their Target Price
May 11Lacklustre Performance Is Driving OraSure Technologies, Inc.'s (NASDAQ:OSUR) Low P/S
Apr 17Earnings Beat: OraSure Technologies, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Mar 01Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing
Feb 29OraSure Technologies, Inc.'s (NASDAQ:OSUR) Business And Shares Still Trailing The Industry
Dec 20Returns On Capital At OraSure Technologies (NASDAQ:OSUR) Have Stalled
Nov 08Industry Analysts Just Upgraded Their OraSure Technologies, Inc. (NASDAQ:OSUR) Revenue Forecasts By 14%
Aug 09Analysts Have Just Cut Their OraSure Technologies, Inc. (NASDAQ:OSUR) Revenue Estimates By 12%
May 16Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing
May 13Party Time: Brokers Just Made Major Increases To Their OraSure Technologies, Inc. (NASDAQ:OSUR) Earnings Forecasts
Feb 17We're Not Very Worried About OraSure Technologies' (NASDAQ:OSUR) Cash Burn Rate
Jan 16OraSure wins $8.6M government contract for next-gen Ebola test
Sep 28OraSure: Revenue Mix Continues To Present Risk
Sep 06Shareholder Returns
| OSUR | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 12.1% | 2.0% | 0.5% |
| 1Y | -28.3% | 6.1% | 15.9% |
Return vs Industry: OSUR underperformed the US Medical Equipment industry which returned 6.1% over the past year.
Return vs Market: OSUR underperformed the US Market which returned 15.9% over the past year.
Price Volatility
| OSUR volatility | |
|---|---|
| OSUR Average Weekly Movement | 6.6% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OSUR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OSUR's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 501 | Carrie Eglinton Manner | www.orasure.com |
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. The company’s products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples.
OraSure Technologies, Inc. Fundamentals Summary
| OSUR fundamental statistics | |
|---|---|
| Market cap | US$219.41m |
| Earnings (TTM) | -US$51.03m |
| Revenue (TTM) | US$138.53m |
Is OSUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OSUR income statement (TTM) | |
|---|---|
| Revenue | US$138.53m |
| Cost of Revenue | US$82.19m |
| Gross Profit | US$56.34m |
| Other Expenses | US$107.37m |
| Earnings | -US$51.03m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.70 |
| Gross Margin | 40.67% |
| Net Profit Margin | -36.84% |
| Debt/Equity Ratio | 0% |
How did OSUR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/25 22:03 |
| End of Day Share Price | 2025/08/25 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OraSure Technologies, Inc. is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charley Jones | Barrington Research Associates, Inc. |
| Karen Koski | BTIG |
| Mark Massaro | Canaccord Genuity |